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ABSTRACT
In the present investigation a novel series of N-(phenyl) chalconyl anthranilic acids containing pyrazolines (4a–j), tetra-
hydropyrimidines (4k–o), tetrahydrothiopyrimidines (4p–t) and 2-phenylquinazolin-4(3H)-ones containing pyrazolines (8a–f),
isoxazolines (8g–l), tetrahydropyrimidines (8m–r) and tetrahydrothiopyrimidines (8s–x) were synthesized and characterized by
elemental analysis, FT-IR, 1H NMR and mass spectroscopy. The title compounds (4a–t) and (8a–x) were investigated for their
analgesic, anti-inflammatory, antimicrobial and in vitro protein denaturation activities. Compounds 4j and 8x were identified
as lead compounds with optimum analgesic, anti-inflammatory and antimicrobial activities.
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1. Introduction
The treatment of pain continues to be the subject of consider-
able pharmaceutical and clinical research. Microbial infections
often produce pain and inflammation. Chemotherapeutic,
analgesic and anti-inflammatory drugs are prescribed simulta-
neously in normal practice. For better patient compliance, an
anti-inflammatory, antimicrobial agent with minimal side effects
is highly desirable, especially in patients with impaired liver or
kidney functions.
Anthranilic acid1 derivatives such as mefenamic acid and
meclofenamate are useful for clinical treatment of various pain
and inflammatory disorders. They were also found to possess
potent analgesic and antimicrobial activities. Compounds
containing the pyrazoline2–6 and isoxazoline6–9 nucleus have
received the attention of medicinal chemists due to a wide range
of biological activities including antimicrobial, analgesic and
anti-inflammatory activities. In recent years there has been an
increased interest in the chemistry of quinazoline-4(3H)-ones
because of their biological significance.10–12 Different types of
quinazoline-4(3H)-ones exhibited antimicrobial, analgesic and
anti-inflammatory13–15 activities. It is a well known fact that
inflammation associated with diseases like arthritis is a conse-
quence of in vivo denaturation of proteins.16 In view of the above
facts and in continuation of our work on pyrazolines2 and
quinazoline-4(3H)-ones,10 we report herein the synthesis of new
molecules possessing analgesic, anti-inflammatory and
antimicrobial activities.
2. Results and Discussion
Synthesis of the title compounds (4a–t) and (8a–x) was carried
as per Schemes 1 and 2. N-(phenyl) chalconyl anthranilic acid1
(3a–e) and 2-phenyl-4H-3,1-benzoxazin-4-one (5)17 were prepared
from anthranilic acid according to methods from the literature.
Condensation of 3a–e separately with hydrazine hydrate
(99 % m/v), phenyl hydrazine, urea and thiourea yielded
N-[5(phenyl)-pyrazoline-3-yl]-anthranilic acids (4a–e), N-[1-
phenyl-5-(substituted)-pyrazoline-3-yl]-anthranilic acids (4f–j),
2-[(2’-oxo-6’-phenyl-1’,2’,5’,6’-tetrahydropyrimidin-4’-yl)
amino]-benzoic acids (4k–o), 2-[(2’-thioxo-6’-phenyl-1’,2’,5’,6’-
tetrahydropyrimidin-4’-yl) amino]-benzoic acids (4p–t) respec-
tively. 2-phenyl-4H-3,1-benzoxazin-4-one (5) on treatment with
p-aminoacetophenone yielded 6 which, on condensation with
araldehydes furnished 3-[4”-{3”-phenylprop-2”-enoyl}
phenyl]-2-phenylquinazolin-4(3H)-ones (7a–f). Further conden-
sation of compounds 7a–f separately with hydrazine hydrate,





phenyl]-2-phenylquinazolin-4(3H ) -ones (8m–r ) and
3-[4”{-2”-thioxo-6”-phenyl-1”,2”,5”,6”-tetrahydropyrimidin-4”-
yl}phenyl]-2-phenylquinazolin-4(3H)-ones (8s–x), respectively.
Structures of newly synthesized compounds were characterized
by elemental analysis, FT-IR, 1H NMR and mass spectroscopy.
Compounds 4a–t, 8a–f and 8m–x showed absorption bands in
the range 3229 to 3291 cm–1 for N-H and 1600 to 1621 cm–1 for
C=N stretching. Compounds 8g–l exhibited absorption bands
in the range 1098 to 1121 cm–1 for C-O-C bending, 1601 to
1612 cm–1 for C=N stretching vibrations and C=O absorption
bands in the range 1650 to 1672 cm–1. 1H NMR spectra of com-
pounds 4a, 4f, 4j and 8a exhibited doublets at δ 3.21, 2.92, 2.86
and 3.06 ppm for -CH2- and triplets at δ 3.95, 3.45, 3.21 and
4.96 ppm for -CH-, respectively. Compounds 4a, 4j, 8a and 8x
showed singlets at δ 8.84, 8.21, 7.20 and 6.76 ppm, respectively,
integrating for one proton due to -NH-, confirming the forma-
tion of the pyrazoline nucleus.
Similarly compounds 4k, 4p, 8m and 8s exhibited doublets at
δ 3.33, 3.07, 2.53 and 2.31 ppm for -CH2-, triplets at δ 4.95, 3.99,
4.62 and 4.41 ppm for -CH- and singlets at δ 6.40, 6.99, 6.14 and
6.79 ppm integrating for one proton due to -NH-, confirming the
formation of the pyrimidine nucleus. In compound 8g disap-
pearance of the -NH- signal and appearance of a doublet at
δ 3.53 ppm and a triplet at δ 5.62 ppm confirmed the formation of
the isoxazoline nucleus. The mass spectra of compounds 4a, 4j,
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4k, 8a, 8g, 8m and 8x showed molecular ion peaks corresponding
to their molecular formulae.
Synthesized compounds 4a–e and 8a–x were evaluated for
analgesic and anti-inflammatory activities. Student’s t-test was
performed to ascertain the significance of the exhibited activities.
The test compounds (100 mg kg–1) and the standard drugs
paracetamol (100 mg kg–1) and mefenamic acid (10 mg kg–1) were
administered in the form of a suspension (1 % carboxymethyl
cellulose as vehicle) by oral route. Analgesic activity of the test
compounds was carried out by the tail flick method18 using
wistar albino mice. The percentage analgesic activity was calcu-
lated in comparison with paracetamol (Table 1). Compounds 4g,
4j, 8a, 8b and 8q exhibited significant analgesic activity after 2 h
of oral administration. Moreover a decrease in analgesic activity
was observed after 3 h of oral administration. In general the
quinazolinone derivatives (8a–x) were found to be more potent
in comparison with pyrazoline/substituted pyrazoline and
tetrahydropyrimidine/tetrahydrothiopyrimidine/substituted
anthranilic acid derivatives (4a–e).
Anti-inflammatory activity of test compounds 4a–t and 8a–x in
acute conditions was investigated using the carrageenan induced
rat paw oedema method of Winter et al.19 Compounds 4d, 4e, 4g,
4i, 4j, 4l, 4n, 4o, 4q, 4s, 4t and 8x exhibited significant anti-
inflammatory activity after 2 h of oral administration. It is also
evident from the results that anti-inflammatory activity
decreased appreciably at 3 h after oral administration. In general
pyrazoline/substituted pyrazoline and tetrahydropyrimidine/
tetrahydrothiopyrimidine/substituted anthranilic acid deriva-
tives of 4a–e were found to be more potent in comparison with
quinazolinone derivatives 8a–x. Compounds 4d, 4e, 4n and 4t
showed maximum anti-inflammatory activity. It is evident from
the findings that pyrazoline and tetrahydropyrimidine/
thiopyrimidine analogues of anthranilic acid bearing an electron
withdrawing para-Cl or ortho-OH respectively in the phenyl ring
at positions 5 and 6’ of the pyrazoline and tetrahydropyri-
midine/thiopyrimidine rings, exhibited significant analgesic and
anti-inflammatory activities. A similar pattern was observed in
the case of 2-phenyl-quinazoline-4(3H)-ones bearing pyra-
zoline, 4,5-dihydroisoxazole, tetrahydropyrimidine at 4’ of
phenyl ring substituents at the 3 position of the 2-phenyl-
quinazoline-4(3H)-one ring. In general, replacement of either
2-OH or 4-Cl substituents with 4-NO2, 4-OCH3 and 2-furyl
groups resulted in a marked decrease of analgesic and anti-
inflammatory activities (Tables 1 and 2).
In vitro anti-inflammatory activity of test compounds 4a–t and
8a–x was investigated using the bovine serum albumin denatur-
ation method20 and the mean percentage inhibition of protein
denaturation was calculated (Table 3). Compounds 4e, 4g, 4j, 4m
and 8f exhibited significant activity compared with the reference
standard mefenamic acid. However, no correlation was observed
between different substituent groups and in vitro percentage
inhibition of denaturation of bovine serum albumin.
All newly synthesized compounds were assayed by the cup
plate method21 against different species of Gram-positive and
Gram-negative bacteria of clinical relevance and against two
strains of pathogenic fungi in order to identify those with maxi-
mum activity as lead compounds. The data obtained for all the
tested species (Table 4) showed varying degrees of activity.
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R=C6H5: 3a, 4(a,f,k,p); 4-NO2C6H4: 3b, 4(b,g,l,q); 4-OCH3C6H4: 3c, 4(c,h,m,r); 2-OHC6H4: 3d, 4(d,i,n,s);
4-ClC6H4: 3e, 4(e,j,o,t).
Scheme 1
Synthesis of anthranilic acid derivatives.
Compounds 4r, 8c, 8e, 8f, 8k, 8l, 8r, and 8x exhibited significant
antibacterial and antifungal activities. In general quinazolinone
derivatives were found to be more active against the entire
tested microorganism.
3. Experimental
3.1. General Synthetic Procedure
Melting points were determined in open capillaries and
are uncorrected. IR spectra were recorded in KBr on a Jasco
FT/IR 5300 spectrophotometer (Tokyo, Japan). 1H NMR (CDCl3)
spectra were recorded on a Bruker DPX-300 MHz spectrometer
(Karslruhe, Germany) using TMS as internal standard. C, H and
N analyses were carried out on a Euro EA (Milan, Italy) analyzer.
Mass spectra were recorded on a Perkin-Elmer Hitachi RMU-6L
MS 30 instrument (Austin, TX, USA). The progress of the reaction
was judged by TLC analysis of the reaction mixture.
3.2. Preparation of N-[5-(phenyl)-pyrazoline-3-yl]-
anthranilic acid (4a)/N-[1-phenyl/substituted phenyl-
5-phenylpyrazoline-3-yl]-anthranilic acid (4f)
A mixture of N-(phenyl) chalconyl anthranilic acid (3a)
(0.01 mol) and hydrazine hydrate/phenyl hydrazine (0.01 mol)
in ethanol (30 mL) was refluxed for 6 h on a water bath. The
reaction mixture was concentrated, cooled and poured into
ice-cold water. The solid thus separated was filtered and
recrystallized from ethanol. Compounds 4b–e and 4g–l were
prepared by adopting the same procedure.
4a: Yield 54 %, m.p. 180–182 °C. IR (KBr) ν: 600 (C=N), 1712
(COOH), 3234 cm–1 (NH). Anal. calcd. for C16H15N3O2 (281): C,
68.35; H, 5.41; N, 14.91 %). Found: C, 68.31; H, 5.37; N, 14.94 %.
MS (m/z): 281, 263, 255, 211, 205, 177, 161, 145, 120, 118, 104, 96, 52.
4b: Yield 63 %, m.p. 225–227 °C. IR (KBr) ν: 1586 (NO2), 1602
(C=N),1716 (COOH), 3229 cm–1 (NH). Anal. calcd. for
C16H14N4O4 (312): C, 58.94; H, 4.28; N, 17.21 %. Found: C, 58.89; H,
4.32; N, 17.17 %.
4c: Yield 57 %, m.p. 145–148 °C. IR (KBr) ν: 1098 (C-O-C), 1608
(C=N), 1710 (COOH), 3236 cm–1 (NH). Anal. calcd. for
C17H17N3O3 (311): C, 65.62; H, 5.51; N, 13.49 %. Found: C, 65.58;
H, 5.50; N, 13.50 %.
4d: Yield 74 %, m.p. 178–180 °C. IR (KBr) ν: 1601 (C=N), 1704
(COOH), 3241 (NH), 3452 cm–1 (OH). Anal. calcd. for C16H15N3O3
(297): C, 64.67; H, 5.12; N, 14.09 %. Found: C, 64.64; H, 5.09; N,
14.13 %.
4e: Yield 65 %, m.p. 158–160 °C. IR (KBr) ν: 732 (C-Cl), 1610
(C=N), 1698 (COOH), 3237 cm–1 (NH). Anal. calcd. for
C16H14N3O2Cl (316): C, 60.83; H, 4.51; N, 13.29 %. Found: C, 60.86;
H, 4.47; N, 13.31 %.
4f: Yield 71 %, m.p. 110–112 °C. IR (KBr) ν: 732 (C-Cl), 1610
(C=N), 1698 (COOH), 3237 cm–1 (NH). Anal. calcd. for
C22H19N3O2 (357): C, 73.89; H, 5.41; N, 11.80 %. Found: C, 73.93; H,
5.36; N, 11.76 %. 1H NMR (CDCl3, 300 MHz), δ: 2.92 (d, 2H, CH2 of
pyrazoline), 3.45 (t,1H, CH of pyrazoline), 6.81–7.84 (m, 14H, aro-
matic proton), 8.25 (s, 1H, NH), 9.65 ppm (s, 1H, COOH).
4g: Yield 67 %, m.p. 280–283 °C. IR (KBr) ν: 1587 (NO2), 1621
(C=N), 1723 cm–1 (COOH). Anal. calcd. for C22H18N4O4 (402): C,
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Scheme 2
Synthesis of 2-phenylquinazoline-4(3H)-one derivatives.
R=C6H5: 7a, 8(a,g,m,s); 4-NO2C6H4: 7c, 8(c,i,o,u); 4-OCH3C6H4: 7d, 8(d,j,p,v); 2-OHC6H4: 7e, 8(e,k,q,w);
4-ClC6H4: 7f, 8(f,l,r,x); 2-furyl: 7b, 8(b,h,n,t)
65.62; H, 4.48; N, 13.90 %. Found: C, 65.66; H, 4.51; N, 13.92 %.
4h: Yield 65 %, m.p. 278–281 °C. IR (KBr) ν: 1112 (C-O-C), 1614
(C=N), 1725 cm–1 (COOH). Anal. calcd. for C23H21N3O3 (387): C,
71.34; H, 5.51; N, 10.90 %. Found: C, 71.30; H, 5.46; N, 10.85 %.
4i: Yield 63 %, m.p. 149–151 °C. IR (KBr) ν: 1618 (C=N), 1731
(COOH), 3462 cm–1 (OH). Anal. calcd. for C22H19N3O3 (373): C,
70.75; H, 5.12; N, 11.28 %. Found: C, 70.76; H, 5.13; N, 11.25 %.
4j: Yield 78 %, m.p. 157–159 °C. IR (KBr) ν: 742 (C-Cl), 1621
(C=N), 1711 cm–1 (COOH). Anal. calcd. for C22H18N3O2Cl (392):
C, 67.41; H, 4.59; N, 10.77 %. Found: C, 67.43; H, 4.63; N, 10.72 %.
1H NMR (CDCl3, 300 MHz), δ: 2.86 (d, 2H, CH2 of pyrazoline),
3.21 (t, 1H, CH of pyrazoline), 6.92–7.69 (m, 14H, aromatic pro-
ton), 8.21 (s, 1H, NH), 10.11 ppm (s, 1H, COOH). MS (m/z): 391,
373, 321, 315, 281, 253, 229, 138, 120, 96, 86, 52.
4k: Yield 65 %, m.p. 188–190 °C. IR (KBr) ν: 1607 (C=N), 1667
(C=O), 1723 (COOH), 3256 cm–1 (NH). Anal. calcd. for
C17H15N3O3 (309): C, 66.06; H, 4.93; N, 13.55 %. Found: C, 66.01; H,
4.89; N, 13.58 %. 1H NMR (CDCl3, 300 MHz), δ: 3.33 (d, 2H, -CH2-
oxypyrimidine), 4.95 (t, 1H, -CH- oxypyrimidine), 6.40 (d, 1H,
NH of oxypyrimidine), 6.81–7.84 (m, 9H, aromatic proton), 8.81
(s, 1H, NH ), 9.60 ppm (s, 1H, COOH). MS (m/z): 309, 291, 281, 266,
205, 189, 172, 161, 145, 120, 118, 114, 96, 52.
4l: Yield 62 %, m.p. 142–144 °C. IR (KBr) ν: 1578 (NO2), 1611
(C=N), 1671 (C=O), 1728 (COOH), 3245 cm–1 (NH). Anal. calcd.
for C17H14N4O5 (354): C, 57.62; H, 3.40; N, 15.79 %. Found: C,
57.63; H, 3.98; N, 15.81 %.
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Table 1 Analgesic activity of synthesized compounds by tail flick
method. Dose: 100 mg kg–1.
Compound Percentage analgesic
activity a
1 h 2 h 3 h
4a 16.4 ± 0.3 c 17.3 ± 0.8 c 5.2 ± 0.5 c
4b 42.2 ± 0.5 c 42.6 ± 0.8 c 16.3 ± 0.6 c
4c 2.4 ± 0.4 c 9.2 ± 0.9 b 10.4 ± 0.5 b
4d 3.3 ± 0.6 c 43.1 ± 0.9 d 17.4 ± 0.6 c
4e 24.3 ± 0.3 c 32.4 ± 0.8 c 23.7 ± 0.6 c
4f 4.6 ± 0.6 b 8.1 ± 0.9 b 7.8 ± 0.6 b
4g 39.8 ± 0.5 c 43.4 ± 0.9 c 23.2 ± 0.8 c
4h 1.4 ± 0.7 c 2.2 ± 0.6 c 2.2 ± 0.6 b
4i 33.2 ± 0.4 c 40.4 ± 0.6 c 33.1 ± 0.6 c
4j 25.4 ± 0.3 c 43.9 ± 0.4 c 32.8 ± 0.6 c
4k 4.4 ± 0.2 b 9.3 ± 0.4 b 10.4 ± 0.6 b
4l 23.9.±0.4 c 42.1 ± 0.4 c 23.8 ± 0.3 c
4m 2.4 ± 0.5 b 5.4 ± 0.5 b 7.2 ± 0.4 b
4n 29.3±0.6 c 43.2±.0.5 c 35.2 ± 0.4 c
4o 27.2 ± 0.6 c 43.4 ± 0.4 c 37.1 ± 0.6 c
4p 4.2 ± 0.5 b 11.5 ± 0.5 b 6.2 ± 0.5 b
4q 26.7 ± 0.5 c 43.4 ± 0.5 c 25.2 ± 0.5 c
4r 2.3 ± 0.5 b 6.2 ± 0.6 b 8.4 ± 0.5 b
4s 25.4 ± 0.6 c 41.8 ± 0.7 c 31.8 ± 0.5 c
4t 26.8 ± 0.8 c 44.6 ± 0.8 c 35.2 ± 0.6 c
8a 12.6 ± 0.7 c 44.2 ± 1.1 c 41.4 ± 0.6 c
8b 16.9 ± 0.6 c 41 ± 0.8 c 4.3 ± 0.6 c
8c 18.4 ± 0.9 c 41.9 ± 0.5 c 41.2 ± 0.6 c
8d 14.8 ± 0.3 c 43.2 ± 0.5 c 42.3 ± 0.4 c
8e 17.9 ± 0.5 c 41.1 ± 0.2 c 39.4 ± 0.4 c
8f 18.1 ± 0.6 c 40.2 ± 0.4 c 42.4 ± 0.4 c
8g 18.3 ± 0.6 c 40.2 ± 0.4 c 43.2 ± 0.5 c
8h 14.4 ± 0.8 c 35.7 ± 0.3 c 35.3 ± 0.5 c
8i 15.7 ± 0.7 c 42.2 ± 0.3 c 41.3 ± 0.5 c
8j 15.6 ± 0.5 c 39.9 ± 0.3 c 42.2 ± 0.5 c
8k 17.3 ± 0.6 c 42.3 ± 0.4 c 41.8 ± 0.5 c
8l 18.2 ± 0.4 c 40.4 ± 0.3 c 42.3 ± 0.6 c
8m 16.6 ± 0.6 c 40.1 ± 0.6 c 31.4 ± 0.6 c
8n 19.3 ± 0.9 c 40.8 ± 0.5 c 25.2 ± 0.5 c
8o 21.8 ± 0.6 c 33.2 ± 0.5 c 19.1 ± 0.6 c
8p 20.9 ± 0.6 c 40.2 ± 0.9 c 24.4 ± 0.8 c
8q 25.1 ± 0.7 c 45.3 ± 0.7 c 35.9 ± 0.8 c
8r 19.3 ± 0.7 c 39.4 ± 1.0 c 25.7 ± 0.6 c
8s 18.8 ± 0.4 c 33.4 ± 0.7 c 20.4 ± 0.6 c
8t 17.4 ± 0.3 c 43.1 ± 0.7 c 25.1 ± 0.3 c
8u 1.3 ± 0.6 d 3.2 ± 0.5 b 2.9 ± 0.4 c
8v 17.3 ± 0.5 c 42.4 ± 0.5 c 31.4 ± 0.5 c
8w 17.2 ± 0.4 c 40.4 ± 0.6 c 25.2 ± 0.6 c
8x 11.7 ± 0.3 c 35.1 ± 0.7 c 28.8 ± 0.5 c
Paracetamol 45.2 ± 0.2 c 52.8 ± 0.7 c 46.2 ± 0.5 c
a Average of three readings; results are expressed as mean ± SEM (n = 6); signifi-
cance levels b P < 0.05, c P < 0.01 and d P < 0.001 compared with the respective
control.
Table 2 Anti-inflammatory activity of synthesized compounds by
carrageenan-induced rat paw oedema method.
Compound Dose/mg kg–1 Percentage anti-inflammatory
activity a
1 h 2 h 3 h
4a 100 29.4 ± 0.4 b 40.3 ± 0.3 c 41.1 ± 0.3 c
4b 100 24.2 ± 0.9 b 49.4 ± 0.4 c 29.2 ± 0.3 b
4c 100 18.3 ± 0.8 b 29.4 ± 0.3 b 29.2 ± 0.5 b
4d 100 50.8 ± 0.5 c 66.2 ± 0.3 c 41.2 ± 0.5 c
4e 100 38.1 ± 0.5 c 58.9 ± 0.3 c 50.3 ± 0.5 c
4f 100 17.9 ± 0.5 c 26.2 ± 0.5 b 24.4 ± 0.6 b
4g 100 37.8 ± 0.8 c 54.7 ± 0.5 b 55.4 ± 0.6 b
4h 100 12.7 ± 0.5 b 17.6 ± 0.5 b 13.3 ± 0.8 c
4i 100 35.2 ± 0.5 c 55.3 ± 0.8 c 42.3 ± 0.6 c
4j 100 3.41 ± 0.7 c 55.1 ± 0.8 b 26.2 ± 0.6 b
4k 100 18.2 ± 0.7 b 33.4 ± 0.8 c 14.8 ± 0.5 b
4l 100 39.7 ± 0.7 b 52.6 ± 0.7 c 37.2 ± 0.9 c
4m 100 39.9 ± 0.7 b 20.2 ± 0.7 b 21.4 ± 0.6 b
4n 100 44.3 ± 0.5 c 60.1 ± 0.7 c 58.9 ± 0.9 c
4o 100 35.2 ± 0.5 c 54.7 ± 0.5 c 41.6 ± 0.6 c
4p 100 4.2 ± 0.7 c 19.3 ± 0.5 b 4.4 ± 0.8 b
4q 100 42.1 ± 0.2 c 57.2 ± 0.5 c 43.2 ± 0.8 c
4r 100 11.3 ± 0.8 b 11.3 ± 0.6 c 1.3 ± 0.6 c
4s 100 35.3 ± 0.7 c 51.8 ± 0.5 c 46.4 ± 0.6 c
4t 100 42.1 ± 0.7 c 60.3 ± 0.5 c 54.4 ± 0.8 b
8a 100 28.3 ± 0.8 c 31.2 ± 0.8 c 23.2 ± 0.8 b
8b 100 22.4 ± 0.8 c 25.4 ± 0.6 c 23.3 ± 0.7 c
8c 100 28.4 ± 0.5 b 31.4 ± 0.6 b 18.4 ± 0.9 b
8d 100 27.8 ± 0.5 c 37.5±0.6 c 23.2 ± 0.7 c
8e 100 32.6 ± 0.5 c 37.5 ± 0.7 c 28.8 ± 0.6 c
8f 100 17.6 ± 0.6 c 19.2 ± 0.6 b 17.9 ± 0.9 c
8g 100 33.1 ± 0.6 c 37.5 ± 0.6 b 18.2 ± 0.9 b
8h 100 11.3 ± 0.6 b 31.4 ± 0.9 b 29.2 ± 0.9 c
8i 100 33.2 ± 0.6 c 37.5±.0.4 c 35.1 ± 0.8 c
8j 100 17.4 ± 0.6 c 25.4 ± 0.4 b 6.2 ± 0.8 b
8k 100 28.4 ± 0.7 b 37.5±.0.8 b 35.3 ± 0.8 b
8l 100 17.1 ± 0.6 b 31.3 ± 0.8 b 18.3 ± 1.1 b
8m 100 16.8 ± 0.7 c 43.7 ± 0.7 c 35.4 ± 0.8 c
8n 100 6.4 ± 0.4 c 30.8 ± 0.7 b 22.7 ± 0.5 b
8o 100 17.3 ± 0.5 c 12.4 ± 0.6 b 6.1 ± 0.5 b
8p 100 6.3 ± 0.2 c 19.1 ± 0.6 c 5.9 ± 0.8 c
8q 100 17.2 ± 0.6 b 31.2 ± 0.5 b 29.2 ± 0.5 c
8r 100 17.1 ± 0.6 c 44.1 ± 0.5 c 34.6 ± 0.5 c
8s 100 21.8 ± 0.4 c 31.2 ± 0.5 b 22.9 ± 0.7 b
8t 100 4.8 ± 0.4 b 12.4 ± 0.7 b 6.2 ± 0.4 b
8u 100 6.1 ± 0.9 c 19.3 ± 0.7 c 6.4 ± 0.6 c
8v 100 11.3 ± 0.9 c 18.6 ± 0.7 c 12.3 ± 0.4 c
8w 100 21.7 ± 0.5 c 44.4 ± 0.6 c 35.1 ± 0.4 c
8x 100 21.8 ± 0.5 c 50.3 ± 0.5 c 41.2 ± 0.4 c
Mefenamic acid 10 56.2 ± 0.5 d 54.2 ± 0.5 d 45.4 ± 0.3 d
a Average of three readings; results are expressed as mean ± SEM (n = 6); signifi-
cance levels b P < 0.05, c P < 0.01 and d P < 0.001 compared with the respective
control.
4m: Yield 81 %, m.p. 166–168 °C. IR (KBr) ν: 1118 (C-O-C), 1612
(C=N), 1669 (C=O), 1731 (COOH), 3255 cm–1 (NH). Anal. calcd.
for C18H17N3O4 (339): C, 63.74; H, 5.09; N, 12.41 %. Found: C,
63.71; H, 5.05; N, 12.38 %.
4n: Yield 69 %, m.p. 171–173 °C. IR (KBr) ν: 1609 (C=N), 1672
(C=O), 1732 (COOH), 3253 (NH), 3484 cm–1 (OH). Anal. calcd.
for C17H15N3O4 (664): C, 62.80; H, 4.67; N, 12.96 %. Found: C,
62.76; H, 4.65; N, 12.92 %.
4o: Yield 65 %, m.p. 156–158 °C. IR (KBr) ν: 746 (C-Cl), 1616
(C=N), 1664 (C=O), 1733 (COOH), 3248 cm–1 (NH). Anal. calcd.
for C17H14N3O3Cl (344): C, 59.44; H, 4.15; N, 12.19 %. Found: C,
59.40; H, 4.10; N, 12.22 %.
3.3. Preparation of 2-[(2’-oxo-6’-phenyl-1’,2’,5’,6’-tetrahydro-
pyrimidin-4’-yl) amino]-benzoic acid (4k)/2-[(2’-thioxo-
6’-phenyl-1’,2’,5’,6’-tetrahydropyrimidin-4’-yl) amino]
benzoic acid (4p)
To a mixture of N-(phenyl) chalconyl anthranilic acid (3a)
(0.01 mol) and urea/thiourea (0.01 mol) in methanol (50 mL), a
few drops of potassium hydroxide solution (2 %) were added
and the mixture refluxed for 9 h on a water bath. The reaction
mixture was concentrated under vacuum and poured into
ice-cold water and allowed to stand overnight. The solid thus
separated was filtered and recrystallized from methanol:water
(1:1). Compounds 4l–o and 4q–t were prepared by adopting the
same procedure.
4p: Yield 72 %, m.p. 184–186 °C. IR (KBr) ν: 1608 (C=N), 1721
(COOH), 3254 cm–1 (NH). Anal. calcd. for C17H15N3O2S (325): C,
62.74; H, 4.61; N, 12.89 %. Found: C, 62.75; H, 4.65; N, 12.91 %. 1H
NMR (CDCl3, 300 MHz), δ: 3.07 (d, 2H, -CH2- of oxypyrimidine),
3.99 (t, 1H, CH thiopyrimidine), 6.99 (d, 1H, NH thiopyrimidine),
7.29–7.84 (m, 9H, aromatic proton), 8.78 (s, 1H, NH), 9.65 ppm (s,
1H, COOH).
4q: Yield 67 %, m.p. 144–146 °C. IR (KBr) ν: 1582 (NO2), 1613
(C=N), 1727 (COOH), 3244 cm–1 (NH). Anal. calcd. for
C17H14N4O4S (370): C, 55.09; H, 3.78; N, 15.17 %. Found: C, 55.13;
H, 3.81; N, 15.13 %.
4r: Yield 68 %, m.p. 165–167 °C. IR (KBr) ν: 1110 (C-O-C), 1609
(C=N), 1722 (COOH), 3263 cm–1 (NH). Anal. calcd. for
C18H17N3O3S (355): C, 60.81; H, 4.78; N, 11.87 %. Found: C, 60.83;
H, 4.82; N, 11.82 %.
4s: Yield 74 %, m.p. 169–170 °C. IR (KBr) ν: 1612 (C=N), 1728
(COOH), 3257 (NH), 3479 cm–1 (OH). Anal. calcd. for
C17H15N3O3S (341): C, 59.78; H, 4.41; N, 12.33 %. Found: C, 59.81;
H, 4.43; N, 12.31 %.
4t: Yield 59 %, m.p. 162–163 °C. IR (KBr) ν: 741 (C-Cl), 1610
(C=N), 1741 (COOH), 3253 cm–1 (NH). Anal. calcd. for
C17H14N3O2SCl (360): C, 56.72; H, 3.96; N, 11.71 %. Found: C,
56.74; H, 3.92; N, 11.68 %.
3.4. Preparation of 3-(4’-acetophenyl)-2-phenylquinazolin-
4(3H)-one (6)
A mixture of 2-phenyl-4H-3,1-benzoxazin-4-one (5) (0.01 mol)
and 4-aminoactophenone (0.01 mol) in dry pyridine (60 mL) was
refluxed for 5 h. The reaction mixture was concentrated, cooled
and poured into ice-cold water. The solid thus separated was
filtered, dried and recrystallized from ethanol.
3.5. Preparation of 3-[4’{-3”-phenylprop-2”-enoyl}phenyl]-
2-phenylquinazolin-4(3H)-one (7a)
To a mixture of 3-(4‘-acetophenyl)-2-phenylquinazolin-4(3H)-one
(6) (0.01 mol) and benzaldehyde (0.01 mol) in methanol (50 mL),
5 mL potassium hydroxide solution (2 %) was added and the
resulting reaction mixture was stirred for 10 h and then refluxed
for 8 h on a water bath. The reaction mixture was concentrated
under vacuum, cooled and poured into ice-cold water and
allowed to stand overnight. The solid thus separated was filtered,
dried and recrystallized from methanol:water (1:1). Compounds
7b–f were prepared by adopting the same procedure.
7a: Yield 56 %, m.p. 156–157 °C IR (KBr) ν: 1602 (C=N),
1657 cm–1 (C=O). Anal. calcd. for C31H26N2O2 (818): C, 80.23; H,
7.69; N, 6.08 %. Found: C, 81.20; H, 5.72; N, 6.11 %. 1H NMR
(CDCl3, 300 MHz), δ: 6.20–6.95 (m, 5H, aromatic proton), 7.41 (d,
1H, -CH- chalcone), 7.87 (d, 1H, -CH- chalcone), 8.12–8.39 ppm
(m, 13H, aromatic proton). MS (m/z): 818 (M+).
7b: Yield 63 %, m.p. 162–163 °C. IR (KBr) ν: 1123 (C-O-C), 1608
(C=N), 1666 cm–1 (C=O). Anal. calcd. for C27H28N2O3 (428): C,
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Table 3 In vitro anti-inflammatory screening of synthesized compounds
by inhibition of bovine serum albumin denaturation.














































Mefenamic acid 0.158 79.54
Control 0.088 0.00
aAverage of three readings.
77.46; H, 4.30; N, 6.73 %. Found: C, 81.20; H, 5.72; N, 6.11 %. MS
(m/z): 428 (M+).
7c: Yield 69 %, m.p. 116–117 °C. IR (KBr) ν: 1587 (NO2), 1602
(C=N), 1672 cm–1 (C=O). Anal. calcd. for C31H25N3O4 (503): C,
73.89; H, 4.97; N, 8.29 %. Found: C, 73.94; H, 5.00; N, 8.34 %. MS
(m/z): 503 (M+).
7d: Yield 71 %, m.p. 148–149 °C. IR (KBr) ν: 1098 (C-O-C), 1611
(C=N), 1668 cm–1 (C=O). Anal. calcd. for C32H28N2O3 (488): C,
78.63; H, 5.81; N, 5.71 %. Found: C, 78.67; H, 5.78; N, 5.73 %. MS
(m/z): 488 (M+).
7e: Yield 75 %, m.p. 146–148 °C. IR (KBr) ν: 1607 (C=N), 1659
(C=O), 3465 cm–1 (OH). Anal. calcd. for C31H26N2O3 (474): C,
78.50; H, 5.49; N, 5.88 %. Found: C, 78.46; H, 5.52; N, 5.90 %. MS
(m/z): 474 (M+).
7f: Yield 78 %, m.p. 154–156 °C. IR (KBr) ν: 749 (C-Cl), 1601
(C=N), 1672 cm–1 (C=O). Anal. calcd. for C31H25N2O2Cl (493): C,
75.49; H, 5.08; N, 5.71 %. Found: C, 75.52; H, 5.11; N, 5.68 %. MS
(m/z): 493 (M+).
3.6. Preparation of 2-phenyl-3-[4’-(5”-phenyl-4,5-dihydro-
1H-pyrazol-3’-yl)phenyl] quinazolin-4(3H)-one (8a)
A mixture of 3-[4’-{3”-phenylprop-2”-enoyl}phenyl]-2-
phenylquinazolin-4(3H)-one (7a) (0.01 mol) and hydrazine
hydrate (0.01 mol) in ethanol (30 mL) was refluxed for 6 h on a
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Table 4 Antimicrobial screening of synthesized compounds by the cup plate method.
Compound Zone of inhibition/mm a
S.a. S.f. E.c. S.t. C.a. A.n.
4a 14 10 13 11 16 12
4b 16 16 15 17 18 18
4c 14 12 10 11 10 12
4d 16 15 17 18 17 17
4e 17 17 16 19 18 19
4f 13 12 13 11 14 14
4g 18 18 17 17 21 20
4h 16 12 12 17 10 12
4i 18 17 18 19 20 21
4j 18 17 19 20 21 19
4k 10 11 11 12 10 09
4l 16 15 16 15 17 16
4m 12 10 11 10 09 08
4n 17 16 17 17 18 17
4o 18 19 18 17 18 18
4p 10 09 08 10 08 08
4q 17 17 16 17 18 17
4r 11 10 10 09 10 08
4s 16 17 17 17 19 16
4t 20 19 19 20 21 22
8a 16 15 16 16 14 12
8b 17 16 16 17 15 14
8c 21 20 22 22 19 18
8d 14 15 14 13 12 10
8e 19 20 20 18 19 17
8f 22 21 22 18 19 19
8g 17 15 15 14 13 13
8h 17 16 16 18 17 16
8i 19 18 20 21 19 18
8j 15 15 16 15 17 13
8k 22 21 20 19 20 19
8l 24 23 22 24 22 21
8m 14 14 13 12 10 09
8n 16 13 12 15 11 11
8o 20 19 17 17 18 16
8p 17 16 15 14 11 09
8q 19 18 18 21 17 16
8r 22 23 24 20 19 21
8s 16 14 15 15 11 10
8t 16 12 13 11 12 10
8u 24 23 21 20 20 18
8v 16 14 14 13 12 15
8w 17 18 19 17 18 16
8x 21 20 22 19 20 21
Ciprofloxacin 29 31 32 26 – –
Clotrimazole – – – – 28 27
DMSO – – – – – –
a Average of three readings.
S. a.: Staphylococcus aureus; S.f.: Staphylococcus faecalis; E.c.: Escherichia coli; S.t.: Salmonella typhi; C.a.: Candida albicans; A.s.: Aspergillus niger.
water bath. The reaction mixture was concentrated, cooled and
poured into ice-cold water. The solid thus separated was filtered,
dried and recrystallized from ethanol. Compounds 8b–f were
prepared by adopting the same procedure.
8a: Yield 71 %, m.p. 192–193 °C. IR (KBr) ν: 749 (C-Cl), 1605
(C=N), 1655 (C=O), 3388 cm–1 (NH). Anal. calcd. for C29H22N4O
(442): C, 78.73; H, 4.97; N, 12.66 %. Found: C, 78.71; H, 5.01; N,
12.63 %. 1H NMR (CDCl3, 300 MHz), δ: 3.06 (d, 2H, -CH2-
pyrazoline), 4.96 (t, 1H, -CH- pyrazoline), 7.20 (s, 1H, NH),
7.39–8.29 ppm (m, 18H, aromatic proton). MS (m/z): 442, 416, 366,
339, 272, 220, 196, 145, 119, 77, 52.
8b: Yield 57 %, m.p. 179–180 °C. IR (KBr) ν: 1121 (C-O-C), 1607
(C=N), 1661 (C=O), 3386 cm–1 (NH). Anal. calcd. for C27H20N4O2
(432): C, 74.93; H, 4.62; N, 12.99 %. Found: C, 74.98; H, 4.66; N,
12.95 %. MS (m/z): 432 (M+).
8c: Yield 63 %, m.p. 132–134 °C. IR (KBr) ν: 1583 (NO2), 1612
(C=N), 1677 (C=O), 3376 cm–1 (NH). Anal. calcd. for C29H21N5O3
(487): C, 71.40; H, 4.29; N, 14.41 %. Found: C, 71.45; H, 4.34; N,
14.37 %. MS (m/z): 487 (M+).
8d: Yield 71 %, m.p. 188–189 °C. IR (KBr) ν: 1090 (C-O-C), 1617
(C=N), 1662 (C=O), 3391 cm–1 (NH). Anal. calcd. for C30H24N4O2
(472): C, 76.22; H, 5.08; N, 11.90 %. Found: C, 76.25; H, 5.12; N,
11.86 %. MS (m/z): 472 (M+).
8e: Yield 76 %, m.p. 162–163 °C. IR (KBr) ν: 1611 (C=N), 1656
(C=O), 3377 (NH), 3462 cm–1 (OH). Anal. calcd. for C29H22N4O2
(458): C, 73.07; H, 4.79; N, 12.19 %. Found: C, 75.97; H, 4.84; N,
11.75 %. MS (m/z): 458 (M+).
8f: Yield 54 %, m.p. 159–161 °C. IR (KBr) ν: 740 (C-Cl), 1613
(C=N), 1670 (C=O), 3382 cm–1 (NH). Anal. calcd. for
C29H21N4OCl (477): C, 75.92; H, 4.42; N, 11.79 %. Found: C, 73.03;
H, 4.44; N, 12.22 %. MS (m/z): 477 (M+).
3.7. Preparation of 2-phenyl-3-[4’-(5”-phenyl-4,5-dihydro-
isoxazol-3’-yl)phenyl] quinazolin-4(3H)-one (8g)
A mixture of 3-[4’-{3”-phenylprop-2”-enoyl}phenyl]-2-
phenylquinazolin-4(3H)-one (7a) (0.01 mol) and hydroxylamine
hydrochloride (0.01 mol) in ethanol (30 mL) was refluxed on a
water bath for 6 h. The reaction mixture was concentrated,
cooled and poured into ice-cold water. The solid thus separated
was filtered, dried and recrystallized from ethanol. Compounds
8h–l were prepared by adopting the same procedure.
8g: Yield 54 %, m.p. 166–167 °C. IR (KBr) ν: 1108 (C-O-C), 1605
(C=N), 1655 cm–1 (C=O). Anal. calcd. for C29H21N3O2 (443): C,
78.50; H, 4.42; N, 11.79 %. Found: C, 78.54; H, 4.81; N, 9.51 %.
1H NMR (CDCl3, 300 MHz), δ: 3.53 (d, 2H, -CH2- isoxazoline), 5.62
(t, 1H, -CH- isoxazoline), 7.20–8.39 ppm (m, 18H, aromatic pro-
ton). MS (m/z): 443, 417, 367, 340, 272, 221, 197, 146, 120, 77, 52.
8h: Yield 57 %, m.p. 172–173 °C. IR (KBr) ν: 1122 (C-O-C), 1601
(C=N), 1663 cm–1 (C=O). Anal. calcd. for C27H19N3O3 (433):
C, 74.79; H, 4.44; N, 9.68 %. Found: C, 74.81; H, 4.42; N, 9.69 %. MS
(m/z): 433 (M+).
8i: Yield 63 %, m.p. 176–177 °C. IR (KBr) ν: 1114 (C-O-C), 1579
(NO2), 1610 (C=N), 1671 cm
–1 (C=O). Anal. calcd. for C29H20N4O4
(488): C, 71.28; H, 4.11; N, 11.51 %. Found: C, 71.30; H, 4.13; N,
1.47 %. MS (m/z): 488 (M+).
8j: Yield 57 %, m.p. 152–153 °C. IR (KBr) ν: 1099 (C-O-C), 1612
(C=N), 1659 cm–1 (C=O). Anal. calcd. for C30H23N3O3 (473): C,
76.12; H, 4.89; N, 8.91 %. Found: C, 76.09; H, 4.90; N, 8.87 %. MS
(m/z): 473 (M+).
8k: Yield 70 %, m.p. 168–170 °C. IR (KBr) ν: 1100 (C-O-C), 1612
(C=N), 1650 (C=O), 3468 cm–1 (OH). Anal. calcd. for C29H21N3O3
(459): C, 75.78; H, 4.59; N, 9.17 %. Found: C, 75.80; H, 4.61;
N, 9.14 %. MS (m/z): 459 (M+).
8l: Yield 73 %, m.p. 196–197 °C. IR (KBr) ν: 738 (C-Cl), 1112
(C-O-C), 1604 (C=N), 1658 cm–1 (C=O). Anal. calcd. for
C29H20N3O2Cl (478): C, 72.91; H, 4.18; N, 8.82 %. Found: C, 72.88;
H, 4.22; N, 8.79 %. MS (m/z): 478 (M+).




To a mixture of 3-[4’-{3”-phenylprop-2”-enoyl}phenyl]-2-
phenylquinazolin-4(3H)-one (7a) (0.01 mol) and urea/thiourea
(0.01 mol) in methanol, a few drops of potassium hydroxide
solution (2 %) were added and the reaction mixture was refluxed
for 9 h on a water bath. After completion of the reaction the
mixture was poured into ice-cold water and allowed to stand
overnight. The solid thus separated was filtered, dried and
recrystallized from methanol:water (1:1). Compounds 8m–r and
8t–x were prepared by adopting the same procedure.
8m: Yield 49 %, m.p. 186–187 °C. IR (KBr) ν: 1602 (C=N), 1667
(C=O), 3380 cm–1 (NH). Anal. calcd. for C30H22N4O2 (470): C,
76.55; H, 4.72; N, 11.94 %. Found: C, 76.58; H, 4.71; N, 11.91 %. 1H
NMR (CDCl3, 300 MHz), δ: 2.53 (d, 2H, -CH2- oxypyrimidine),
4.62 (t, 1H, -CH- oxypyrimidine), 6.14 (d, 1H, -NH oxypyri-
midine), 7.20–8.39 ppm (m, 18H, aromatic proton). MS (m/z): 470,
444, 427, 367, 272, 222, 197, 147, 77, 52.
8n: Yield 71 %, m.p. 190–191 °C. IR (KBr) ν: 1122 (C-O-C), 1600
(C=N), 1668 (C=O), 3378 cm–1 (NH). Anal. calcd. for C28H20N4O3
(460): C, 73.07; H, 4.41; N, 12.16 %. Found: C, 73.03; H, 4.38; N,
12.17 %. MS (m/z): 460 (M+).
8o: Yield 67 %, m.p. 144–145 °C. IR (KBr) ν: 1579 (NO2), 1610
(C=N), 1671 (C=O), 3375 cm–1 (NH). Anal. calcd. for C30H21N5O4
(515): C, 69.91; H, 4.07; N, 13.62 %. Found: C, 69.89; H, 4.11; N,
13.58 %. MS (m/z): 515 (M+).
8p: Yield 68 %, m.p. 159–153 °C. IR (KBr) ν: 1099 (C-O-C), 1612
(C=N), 1659 (C=O), 3386 cm–1 (NH). Anal. calcd. for C31H24N4O3
(500): C, 74.41; H, 4.79; N, 11.21 %. Found: C, 74.38; H, 4.83; N,
11.19 %. MS (m/z): 500 (M+).
8q: Yield 65 %, m.p. 155–156 °C. IR (KBr) ν: 1612 (C=N), 1650
(C=O), 3371 (NH), 3468 cm–1 (OH). Anal. calcd. for C30H22N4O3
(486): C, 74.02; H, 4.60; N, 11.49 %. Found: C, 74.06; H, 4.56;
N, 11.52 %. MS (m/z): 486 (M+).
8r: Yield 72 %, m.p. 162–163 °C. IR (KBr) ν: 738 (C-Cl), 1604
(C=N), 1658 (C=O), 3378 cm–1 (NH). Anal. calcd. for
C30H21N4O2Cl (505): C, 74.02; H, 4.21; N, 11.12 %. Found: C, 71.36;
H, 4.19; N, 11.10 %. MS (m/z): 505 (M+).
8s: Yield 74 %, m.p. 178–179 °C. IR (KBr) ν: 1605 (C=N), 1657
(C=O), 3380 cm–1 (NH). Anal. calcd. for C30H22N4OS (486): C,
74.09; H, 4.60; N, 11.48 %. Found: C, 74.05; H, 4.56; N, 11.51 %.
1H NMR (CDCl3, 300 MHz), δ: 2.31 (d, 2H, -CH2- thiopyrimidine),
4.41 (t, 1H, -CH- of thiopyrimidine), 6.79 (d, 1H, NH of thiopyri-
midine), 7.20–8.37 ppm (m, 18H, aromatic proton). MS (m/z): 486
(M+).
8t: Yield 77 %, m.p. 189–190 °C. IR (KBr) ν: 1126 (C-O-C), 1604
(C=N), 1657 (C=O), 3371 cm–1 (NH). Anal. calcd. for C28H20N4O2S
(476): C, 70.61; H, 4.24; N, 11.81 %. Found: C, 70.57; H, 4.23;
N, 11.5 %. MS (m/z): 476 (M+).
8u: Yield 68 %, m.p. 147–148 °C. IR (KBr) ν: 1583 (NO2), 1608
(C=N), 1667 (C=O), 3371 cm–1 (NH). Anal. calcd. for C30H21N5O3S
(531): C, 67.82; H, 3.99; N, 13.14 %. Found: C, 67.78; H, 3.98;
N, 13.17 %. MS (m/z): 531(M+).
8v: Yield 58 %, m.p. 162–163 °C. IR (KBr) ν: 1102 (C-O-C), 1605
(C=N), 1657 (C=O), 3385 cm–1 (NH). Anal. calcd. for C31H24N4O2S
(516): C, 72.11; H, 4.72; N, 10.81 %. Found: C, 72.07; H, 4.68;
N, 10.85 %. MS (m/z): 516 (M+).
8w: Yield 74 %, m.p. 153–154 °C. IR (KBr) ν: 1610 (C=N), 1662
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(C=O), 3379 (NH), 3461 cm–1 (OH). Anal. calcd. for C30H22N4O2S
(502): C, 71.73; H, 4.38; N, 11.16 %. Found: C, 71.69; H, 4.41;
N, 11.15 %. MS (m/z): 502 (M+).
8x: Yield 82 %, m.p. 166–167 °C. IR (KBr) ν: 747 (C-Cl), 1611
(C=N), 1672 (C=O), 3383 cm–1 (NH). Anal. calcd. for
C30H21N4OSCl (520): C, 69.20; H, 4.10; N, 10.71 %. Found: C, 69.16;
H, 4.06; N, 10.75 %. 1H NMR (CDCl3, 300 MHz), δ: 2.33 (d, 2H,
-CH2- thiopyrimidine), 4.74 (t, 1H, -CH- of thiopyrimidine), 6.76
(d, 1H, NH of thiopyrimidine), 7.21–8.52 ppm (m, 18H, aromatic
proton). MS (m/z): 520, 494, 460, 417, 298, 272, 197, 86, 51.
4. Biological Activity
The synthesized compounds were evaluated for analgesic and
anti-inflammatory activities. Student’s t-test was performed to
ascertain the significance of the exhibited activities. The test
compounds and standard drugs were administered in the form
of a suspension (1 % carboxymethyl cellulose as vehicle) by an
oral route. Each group consisted of six animals. Animals were
procured from Orissa University of Agriculture and Technology,
Bhubaneswar, Orissa, and were maintained in colony cages at
23 ± 2 °C, and a relative humidity of 45–50 %, maintained under
12 h light and dark cycle and fed with standard rat pellet diet
(Hindustan Liver Ltd., Mumbai, India). Prior approval of the
local Animal Ethical Committee was obtained to carry out the
experimental work on the animals.
Acute oral toxicity was performed for the compounds 4a–t and
8a–x following the Organization of Economic Cooperation and
Development guidelines (OECD-423) (acute toxic class method).
Swiss albino mice (n = 3) of either sex selected by random
sampling were used for the study. The animals were fasted for
3–4 h with water ad libitum, after which the test compounds (1 %
suspension in CMC) were administered orally at doses of 50, 100,
250, 500 and 1000 mg kg–1 and the mice observed for three days.
In the present study, mortality was not observed even at 1000 mg
kg–1, indicating that the compounds are non-toxic to animals.
4.1. Analgesic Activity
The analgesic activity was determined by the tail flick
method.16 Paracetamol (100 mg kg–1) was administered as a
standard drug for comparison. Test compounds (100 mg kg–1)
were administered orally by intragastric tube. The animals were
held in position by a suitable restrainer with the tail extending
out and the tail (up to 5 cm) was then dipped in a beaker of water
maintained at 55 ± 5 °C. The time in seconds taken to withdraw
the tail clearly out of water was taken as the reaction time. Three
readings for each animal were recorded at 30, 60, 120 and
180 min after administration of compounds. A cut off point of
10 s was observed to prevent damage to the tail. The results are
presented in Table 1.
4.2. Anti-inflammatory Activity
Anti-inflammatory activity was determined by the carra-
geenan-induced rat paw oedema method17 in albino rats (n = 6)
of either sex (100–140 g). Mefenamic acid (10 mg kg–1) was ad-
ministered as a standard drug. The test compounds were admin-
istered (100 mg kg–1) orally 30 min prior to the administration of
carrageenan in the right hind paws of the rats. The paw thickness
was measured three times using vernier callipers at 30, 60, 120
and 180 min after carrageenan administration. Results are
presented in Table 2.
4.3. Inhibition of Protein Denaturation
The reaction mixtures (0.5 mL) consisted of 0.45 mL bovine
serum albumin (5 % aqueous solution) and 0.05 mL of synthe-
sized compound (100 µg mL–1 of final volume). pH was adjusted
at 6.3 using a small amount of 1 mol L–1 HCl. The samples were
incubated at 37 °C for 20 min and then heated at 57 °C for 3 min.
After cooling the samples, 2.5 mL phosphate buffer saline
(pH 6.3) was added to each tube. Turbidity was measured spec-
trophotometrically at 660 nm.18 For control tests 0.05 mL distilled
water was used instead of the synthesized compound. Mefe-
namic acid (10 µg mL–1) was used as reference standard for
comparison of the protein denaturation property. Results are
presented in Table 3.
4.4. Antimicrobial/Antifungal Activity
In vitro antimicrobial study was carried on Muller Hinton agar
(Hi-media) plates (37 °C, 24 h) by the agar diffusion cup plate
method.19 The test microorganisms were obtained from the
Department of Microbiology, Orissa University of Agriculture
and Technology, Orissa, India. All the compounds were
screened for antimicrobial activity at the 100 µg mL–1 concentra-
tion level against the following bacterial strains: Staphylococcus
aureus, Staphylococcus feacalis, Escherichia coli and Salmonella typhi.
Antifungal activity was tested on Sabouraud dextrose agar
(Himedia) plates (26 °C, 48–72 h) by the cup plate method19
against Candida albicans and Aspergillus niger at a concentration
level of 100 µg mL–1. Ciprofloxacin and clotrimazole were used as
reference standards for comparison of antibacterial and anti-
fungal activity. DMSO was used as a solvent control for both
antibacterial and antifungal activities. The results are presented
in Table 4.
5. Conclusion
In summary, we have prepared a series of novel N-[substituted
pyrazoline-3-yl]-anthranilic acids (4a–t) and 2-phenyl quina-
zolin-4(3H)-ones (8a–x), from which compounds 4j and 8x were
identified as lead compounds with optimum analgesic,
anti-inflammatory and antimicrobial activities. Further investi-
gations of the biological profiles of these selected compounds are
in progress.
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